Results 1 to 10 of about 15,480,873 (292)

Transcranial magnetic stimulation in cocaine use disorder and the risk of seizure: a review of the evidence [PDF]

Frontiers in Psychiatry
Transcranial magnetic stimulation (TMS) has emerged as a promising intervention for cocaine use disorder (CUD). However, a key concern when employing TMS in CUD is the potential risk of seizures.
Caesar G. Imperio, Caesar G. Imperio, Eric Parmon, Eric Parmon, Vaughn R. Steele, Vaughn R. Steele, Vaughn R. Steele, Derek Blevins, Derek Blevins, Rebecca Chalme, Rebecca Chalme, Jonathan M. Wai, Jonathan M. Wai, Kathleen Brady, Markus Heilig, Colleen A. Hanlon, Colleen A. Hanlon, Frances R. Levin, Frances R. Levin, Diana Martinez, Diana Martinez   +20 more
doaj   +2 more sources

Cocaine Use Disorder (CUD): Current Clinical Perspectives

Substance Abuse and Rehabilitation, 2022
Elizabeth KC Schwartz,1,2 Noah R Wolkowicz,1,2 Joao P De Aquino,1,2 R Ross MacLean,1,2 Mehmet Sofuoglu1,2 1Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA; 2Department of Psychiatry, VA Connecticut Healthcare System, West
Schwartz EKC, Wolkowicz NR, De Aquino JP, MacLean RR, Sofuoglu M   +4 more
doaj   +2 more sources

N-acetylcysteine reduces prefrontal reactivity to cocaine cues in individuals with cocaine use disorder [PDF]

Frontiers in Psychiatry
BackgroundIndividuals with cocaine use disorder experience heightened motivation to pursue rewards tied to cocaine, often triggered by associated cues.
Etna J. E. Engeli, Katrin H. Preller, Nathalie M. Rieser, Nathalie M. Rieser, Johanna Klar, Johanna Klar, Philipp Staempfli, Lea M. Hulka, Matthias Kirschner, Matthias Kirschner, Erich Seifritz, Erich Seifritz, Marcus Herdener   +12 more
doaj   +2 more sources

A preliminary evaluation of N-acetylcysteine's effects on patient adherence to treatment for cocaine use disorder [PDF]

Mental Health Clinician, 2023
Introduction: Cocaine use disorder (CUD) is a disabling disease associated with high rates of relapse and intense cravings. Patients with CUD struggle to adhere to treatment, which contributes to relapse and frequent readmissions to residential rehab (RR)
Jake Schechter, DNP, PMHNP-BC, RN, Geoffrey W. Brown, PharmD, Maria Janda, PharmD   +2 more
doaj   +1 more source

Cocaine use disorder patients develop distinct patterns of regulation of acth secretion by a vasopressin agonist and oxytocin: Report on a laboratory study

Drug and Alcohol Dependence Reports, 2023
Background: : Oxytocin and Vasopressin systems in the brain sustain adaptation to stressors. Cocaine being a stressor, it may alter brain homeostatic function. This dysregulation may entrench cocaine use disorder.
Wilfrid Noël Raby, Matthew Heller, Demetrios Milliaressis, C. Jean Choi, Cale Basaraba, Frances R. Levin, Sarah Church, Martina Pavlicova, Edward V. Nunes   +8 more
doaj   +1 more source

Identification of Functional CircRNA–miRNA–mRNA Regulatory Network in Dorsolateral Prefrontal Cortex Neurons of Patients With Cocaine Use Disorder

Frontiers in Molecular Neuroscience, 2022
Increasing evidence has indicated that circular RNAs (circRNAs) act as competing endogenous RNAs (ceRNAs) regulatory network to regulate the expression of target genes by sponging microRNAs (miRNAs), and therefore play an essential role in many ...
Yun Chen, Yun Chen, Xianfeng Li, Shiqiu Meng, Shihao Huang, Suhua Chang, Jie Shi, Jie Shi   +7 more
doaj   +1 more source

Use of sustained release dextroamphetamine for the treatment of stimulant use disorder in the setting of injectable opioid agonist treatment in Canada: a case report

Harm Reduction Journal, 2021
Background For people with opioid use disorder who are not responding to oral opioid agonist treatment, evidence supports the effectiveness of injectable opioid agonist treatment with injectable hydromorphone (an opioid analgesic) and diacetylmorphine ...
Heather Palis, Scott MacDonald, Jennifer Jun, Eugenia Oviedo-Joekes   +3 more
doaj   +1 more source

Genetic and epigenetic analysis of the serotonin 2A receptor in the context of cocaine abuse

Epigenetics, 2022
Despite more than 2 million American cocaine users monthly, there is no approved drug for treating cocaine use disorder. Cocaine use disorder has a multifactorial aetiology, including both genetic and environmental factors.
Aysheh Alrfooh, Ryan M. Smith
doaj   +1 more source

Schizoaffective disorder induced by substance abuse: a case report

European Psychiatry, 2022
Introduction We present the case of a 33-year old man that suffer chronic cocaine and cannabis use since adolescence and at age of 25 develops depressive symptoms and later psychotic symptoms not congruent with mood state.
A. García Carpintero, B. Rodado León, A. Bermejo Pastor, M. Jiménez Cabañas, T. Ponte López   +4 more
doaj   +1 more source

Sociodemographic and clinical profile of crack cocaine treatment-seeking individuals living in “Crackland”, Brazil

Jornal Brasileiro de Psiquiatria, 2022
Objective: São Paulo‘s Crackland is the biggest and oldest open drug use scene in Brazil, yet little is known about the profile of crack cocaine treatment-seeking individuals living in this region.
André Q. C. Miguel, Viviane Simões, Rodolfo Yamauchi, Clarice S. Madruga, Claudio J. da Silva, Ronaldo R. Laranjeira, John M. Roll, Crystal L. Smith, Sterling M. McPherson, Jair J. Mari   +9 more
doaj   +1 more source